Oncology Medicines & Precision Diagnostics

Cancer care links therapeutic franchises with molecular testing that helps select treatments and monitor disease. This basket pairs established oncology drug businesses and cancer-vaccine development with specialists in tumor profiling and residual-disease detection, rather than a general drugmaker allocation. Upcoming earnings across the therapeutic holdings provide opportunities to reassess commercial execution, while clinical and reimbursement uncertainty remain key risks. Launch basket (equal weight): MRK, ABBV, AMGN, LLY, MRNA, REGN, INCY, GH, NTRA, TEM Rules: 1. No inverse, leveraged or volatility ETFs. 2. Only names tradable at the enrolled brokers (Moomoo): no OTC listings, no dead tickers, nothing on the refused list.